Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Satoko Koga

Showing results (11-20 of 25) with videos related to

Pageof 3
Sort By:
Cellular Immunology|November 2, 2020
NFκB and TGFβ contribute to the expression of PTPN3 in activated human lymphocytesKazunori Nakayama, Hideya Onishi, Akiko Fujimura, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|April 25, 2012
A translocator protein ligand PK11195 shows antigrowth activity in human choriocarcinoma cellsNoriyuki Takai, Naoko Kira, Terukazu Ishii, et al.
Anticancer Research|May 31, 2022
PTPN3 Could Βe a Therapeutic Target of Pancreatic CancerHideya Onishi, Naoya Iwamoto, Keita Sakanashi, et al.
Anticancer Research|June 23, 2023
MAML3 Contributes to Induction of Malignant Phenotype of Gallbladder Cancer Through Morphogenesis Signalling Under HypoxiaLin Na, Hideya Onishi, Shinji Morisaki, et al.
Journal of Cancer Research and Clinical Oncology|August 16, 2023
PTPN3 inhibition contributes to the activation of the dendritic cell function to be a promising new immunotherapy targetNaoya Iwamoto, Hideya Onishi, Shogo Masuda, et al.
Journal of Cancer|March 5, 2020
FAM115C could be a novel tumor suppressor associated with prolonged survival in pancreatic cancer patientsKiyoshi Saeki, Hideya Onishi, Satoko Koga, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|December 14, 2019
Patched 1-interacting Peptide Represses Fibrosis in Pancreatic Cancer to Augment the Effectiveness of ImmunotherapyYasuhiro Oyama, Hideya Onishi, Satoko Koga, et al.
International Journal of Surgery Case Reports|April 25, 2017
Eosinophilic funiculitis initially diagnosed as irreducible inguinal hernia: A case reportKohei Yamada, Akashi Ikubo, Shota Ikeda, et al.
Translational Oncology|June 16, 2021
PTPN3 is a potential target for a new cancer immunotherapy that has a dual effect of T cell activation and direct cancer inhibition in lung neuroendocrine tumorSatoko Koga, Hideya Onishi, Shogo Masuda, et al.
Japanese Journal of Clinical Oncology|April 7, 2004
Absence of mutations in the Wilms' tumor gene WT1 in primary breast cancerYusuke Oji, Yasuo Miyoshi, Eiji Kiyotoh, et al.
Pageof 3

Showing results (11-20 of 25) with videos related to

Sort By:
Pageof 3
Cellular Immunology|November 2, 2020
NFκB and TGFβ contribute to the expression of PTPN3 in activated human lymphocytesKazunori Nakayama, Hideya Onishi, Akiko Fujimura, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|April 25, 2012
A translocator protein ligand PK11195 shows antigrowth activity in human choriocarcinoma cellsNoriyuki Takai, Naoko Kira, Terukazu Ishii, et al.
Anticancer Research|May 31, 2022
PTPN3 Could Βe a Therapeutic Target of Pancreatic CancerHideya Onishi, Naoya Iwamoto, Keita Sakanashi, et al.
Anticancer Research|June 23, 2023
MAML3 Contributes to Induction of Malignant Phenotype of Gallbladder Cancer Through Morphogenesis Signalling Under HypoxiaLin Na, Hideya Onishi, Shinji Morisaki, et al.
Journal of Cancer Research and Clinical Oncology|August 16, 2023
PTPN3 inhibition contributes to the activation of the dendritic cell function to be a promising new immunotherapy targetNaoya Iwamoto, Hideya Onishi, Shogo Masuda, et al.
Journal of Cancer|March 5, 2020
FAM115C could be a novel tumor suppressor associated with prolonged survival in pancreatic cancer patientsKiyoshi Saeki, Hideya Onishi, Satoko Koga, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|December 14, 2019
Patched 1-interacting Peptide Represses Fibrosis in Pancreatic Cancer to Augment the Effectiveness of ImmunotherapyYasuhiro Oyama, Hideya Onishi, Satoko Koga, et al.
International Journal of Surgery Case Reports|April 25, 2017
Eosinophilic funiculitis initially diagnosed as irreducible inguinal hernia: A case reportKohei Yamada, Akashi Ikubo, Shota Ikeda, et al.
Translational Oncology|June 16, 2021
PTPN3 is a potential target for a new cancer immunotherapy that has a dual effect of T cell activation and direct cancer inhibition in lung neuroendocrine tumorSatoko Koga, Hideya Onishi, Shogo Masuda, et al.
Japanese Journal of Clinical Oncology|April 7, 2004
Absence of mutations in the Wilms' tumor gene WT1 in primary breast cancerYusuke Oji, Yasuo Miyoshi, Eiji Kiyotoh, et al.
Pageof 3